Topics

Evaluating the Safety of Immunotherapy in NSCLC Patients With Comorbidities

20:00 EDT 9 Sep 2019 | Cancer Networks

Combination immunotherapy with nivolumab plus ipilimumab was examined as a first-line therapy for patients with advanced non–small-cell lung cancer. Results were presented at the International Associate for the Study of Lung Cancer 2019 World Conference on Lung Cancer.

Original Article: Evaluating the Safety of Immunotherapy in NSCLC Patients With Comorbidities

NEXT ARTICLE

More From BioPortfolio on "Evaluating the Safety of Immunotherapy in NSCLC Patients With Comorbidities"

Quick Search

Relevant Topic

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...